Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study

Talazoparib (Talzenna) is a novel poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor that is clinically used for the therapy of breast cancer. Furthermore, the drug has shown antitumor activity against different cancer types, including non-small cell lung cancer (NSCLC). In this work, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabet, Ziba, Vagiannis, Dimitrios, Budagaga, Youssif, Zhang, Yu, Novotná, Eva, Hanke, Ivo, Rozkoš, Tomáš, Hofman, Jakub
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697930/
https://www.ncbi.nlm.nih.gov/pubmed/36430819
http://dx.doi.org/10.3390/ijms232214338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697930/
https://www.ncbi.nlm.nih.gov/pubmed/36430819
http://dx.doi.org/10.3390/ijms232214338

Ejemplares similares